Search Results

XtalPi Inc., a leading global technology company in integrating artificial intelligence and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer.

XtalPi Inc., a leading technology platform company renowned for melding physics-based computation, artificial intelligence, and robotics to advance the discovery and evolution of groundbreaking medicines and innovative materials, unveiled its newest brand, XtalPi Intelligent Automation, at the inaugural Intelligent Automation Forum on August 25th, 2023, in Shanghai, China.

XtalPi Inc. and the Advanced Biomedical Instrumentation Centre at the University of Hong Kong have entered a memorandum of understanding that outlines a roadmap for scientific collaboration and commercialization of deep tech developed by ABIC researchers located both in Hong Kong and globally.

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company.

Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development.

XtalPi, Inc., a privately-held solution provider accelerating biopharmaceutical research via its integrated technology platform, announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) to deliver chemical matter with validated binding affinities and desirable property profiles.

XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations.

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group.

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, today announced a strategic collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), to discover novel treatment candidates for non-small cell lung cancer (NSCLC).

Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.